ValuentumAd

Official PayPal Seal
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Latest Valuentum Commentary

Nov 10, 2016
Assessing Reactions to Trump’s Victory
Image Source: Gage Skidmore. Donald Trump will be the 45th President of the United States of America. Let’s dig into some of the reactions across the market. We’re keeping our cool.
Oct 28, 2016
Podcast: Markets In Motion
The Valuentum analyst team covers market moving information that is top of mind from consumer staples valuations, the political election cycle, utility valuations, energy resource pricing, biotech considerations, Brexit uncertainty and beyond. ~8 minutes.
Aug 10, 2016
Oncology News a Key Driver of Big Pharma
Image Source: Images Money. Oncology product portfolios and pipelines have been key factors in the big pharma industry as of late.
Apr 21, 2016
The Market – On Its Head
Let’s discuss what’s been working and what’s not been working in today’s market.
Mar 15, 2016
Valeant’s Back Firmly Up Against the Wall
Image: A bottle of Valeant's anti-depression drug Wellbrutin lay in disarray, much like the company's operations. Wellbrutin was one of several key drugs on which Valeant used questionable pricing strategies to increase sales, source: Wendy. Valeant shares have been punished by the market for a combination of poor performance, a weak outlook, legal, political and financial trouble, and the warning of the potential for default.
Feb 11, 2016
More Market Weakness: We Haven’t Hit Bottom Yet
Janet Yellen fails to spark market buying. Global equity market weakness ensues.
Feb 2, 2016
Best Idea Michael Kors Up 20%+ -- Yawn?
It’s good to see a recent add make a move such as this, but let’s cover other areas in this note as well.
Jan 29, 2016
Alerts: High-grading! GILD-->JNJ; EBAY-->FB
We’re “high-grading” the Best Ideas Newsletter portfolio.
Oct 28, 2015
Around the Horn in Biotech/Pharma: 3Q Earnings Review
Abbott, Biogen, Bristol-Myers, Eli Lilly, Gilead, GlaxoSmithKline, Merck, Pfizer…


Latest News and Media
The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.